What is Arpeggio Bio?
Arpeggio Bio operates at the intersection of advanced genomics and computational biology. By integrating state-of-the-art sequencing methodologies with sophisticated machine learning algorithms, the company provides unparalleled insights into the biological mechanisms of action for various compounds. This dual-pronged approach allows Arpeggio Bio to decode complex cellular responses, effectively bridging the gap between raw biological data and actionable therapeutic discovery. As a key player in the drug discovery ecosystem, the firm is redefining how researchers identify and validate novel targets, thereby streamlining the path from laboratory bench to clinical application.
How much funding has Arpeggio Bio raised?
Arpeggio Bio has raised a total of $20.2M across 2 funding rounds:
Angel/Seed
$3.2M
Series A
$17M
Angel/Seed (2020): $3.2M with participation from FundersClub, Fifty Years, Y Combinator, TechU, and Khosla Ventures
Series A (2022): $17M led by Khosla Ventures Acquisition, FundersClub, Builders VC, and TechU Ventures
Key Investors in Arpeggio Bio
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, specializing in breakthrough technologies across sectors including health, AI, and sustainable energy.
FundersClub
An online venture capital platform that connects accredited investors with highly vetted startups, providing essential capital to foster innovation.
Y Combinator
A premier startup accelerator based in Mountain View, known for providing seed funding and strategic mentorship to high-growth technology companies.
What's next for Arpeggio Bio?
With the infusion of capital from its latest funding round, Arpeggio Bio is poised to scale its technological infrastructure and expand its collaborative research efforts. The company is expected to prioritize the enhancement of its machine learning models to increase the predictive accuracy of its sequencing platform. Furthermore, the strategic focus will likely shift toward establishing high-value partnerships with pharmaceutical entities, aiming to integrate its proprietary insights into broader drug development pipelines. As the firm matures, its ability to maintain a competitive edge in data-driven biology will be critical to sustaining its growth trajectory and delivering long-term value to its stakeholders.
See full Arpeggio Bio company page
